- Home
- MGTX vs AVIR Comparison
MGTX vs AVIR Comparison
Compare MGTX & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- AVIR
- Stock Information
- Founded
- MGTX 2015
- AVIR 2012
- Country
- MGTX United States
- AVIR United States
- Employees
- MGTX N/A
- AVIR N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- MGTX Health Care
- AVIR Health Care
- Exchange
- MGTX Nasdaq
- AVIR Nasdaq
- Market Cap
- MGTX 479.9M
- AVIR 247.5M
- IPO Year
- MGTX N/A
- AVIR 2020
- Fundamental
- Price
- MGTX $5.92
- AVIR $3.20
- Analyst Decision
- MGTX Strong Buy
- AVIR Hold
- Analyst Count
- MGTX 2
- AVIR 1
- Target Price
- MGTX $23.50
- AVIR $6.88
- AVG Volume (30 Days)
- MGTX 314.5K
- AVIR 558.7K
- Earning Date
- MGTX 11-13-2024
- AVIR 02-26-2025
- Dividend Yield
- MGTX N/A
- AVIR N/A
- EPS Growth
- MGTX N/A
- AVIR N/A
- EPS
- MGTX N/A
- AVIR N/A
- Revenue
- MGTX $13,929,000.00
- AVIR N/A
- Revenue This Year
- MGTX N/A
- AVIR N/A
- Revenue Next Year
- MGTX $1,391.84
- AVIR N/A
- P/E Ratio
- MGTX N/A
- AVIR N/A
- Revenue Growth
- MGTX 108.24
- AVIR N/A
- 52 Week Low
- MGTX $3.85
- AVIR $2.75
- 52 Week High
- MGTX $7.37
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- MGTX 44.92
- AVIR 46.02
- Support Level
- MGTX $5.60
- AVIR $3.11
- Resistance Level
- MGTX $6.12
- AVIR $3.60
- Average True Range (ATR)
- MGTX 0.34
- AVIR 0.12
- MACD
- MGTX -0.04
- AVIR -0.01
- Stochastic Oscillator
- MGTX 30.19
- AVIR 18.40
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).